Clinical Trial Results:
SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation.
An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients with Atrial Fibrillation undergoing Electric Cardioversion Following Transesophageal Echocardiography.
Summary
|
|
EudraCT number |
2008-000789-22 |
Trial protocol |
DE FR |
Global completion date |
06 Sep 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Feb 2016
|
First version publication date |
01 Nov 2014
|
Other versions |
|
Summary report(s) |
111418-FDAAA-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.